Paeds Vivas · allergy-and-immunology
T-cell and combined immunodeficiencies — branching viva
Branching structured-oral viva on T-cell and combined immunodeficiencies: why loss of T cells collapses the whole adaptive immune system, the SCID immunophenotypes and their leading genetic causes, the newborn screen by TREC and the transplant timing-outcome relationship, the danger of live vaccines and non-irradiated blood, and the syndromic CID (DiGeorge/22q11.2, Wiskott-Aldrich, Omenn, ataxia-telangiectasia).
On this page
Study tools
Target exams
Opening question
Examiner: Take me through this infant. What does the low TREC result mean, and what is your frame for managing him? [1]
Candidate: A low T-cell receptor excision circle result on the newborn screen means this infant has few naive T cells leaving the thymus, which raises SCID as the leading diagnosis. My frame is that SCID is a medical emergency — it is fatal within the first one to two years without curative therapy — so I need to confirm the diagnosis with flow cytometry, protect the infant from iatrogenic harm while the diagnosis is secured, and refer urgently to a transplant centre, because the timing of haematopoietic stem cell transplantation — before infection and ideally before 3.5 months of age — is the single most powerful determinant of survival. [1]
Examiner: The family history is interesting. Why does it matter? [1]
Candidate: A maternal uncle who died in infancy before a diagnosis was made is the classic pedigree for X-linked SCID. The IL2RG mutation is carried by the mother, and affected male infants on the maternal line present and die without a diagnosis if newborn screening is not available. This history, combined with the low TREC result and the low lymphocyte count, makes X-linked SCID the leading diagnosis, and flow cytometry is likely to show the T⁻B⁺NK⁻ pattern. [1]
References7ShowHide
- [1]Kwan A; Abraham RS; Currier R; Brower A; Andruszewski K; Abbott JK; Baker M; Ballow M Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA, 2014.PMID 25138334
- [2]Pai SY; Logan BR; Griffith LM; Buckley RH; Parrott RE; Dvorak CC; Kapoor N; Hanson IC Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med, 2014.PMID 25075835
- [3]McDonald-McGinn DM; Sullivan KE; Marino B; Philip N; Swillen A; Vorstman JA; Zackai EH; Emanuel BS 22q11.2 deletion syndrome. Nat Rev Dis Primers, 2015.PMID 27189754
- [6]Poli MC; Aksentijevich I; Bousfiha AA; Cunningham-Rundles C; Hambleton S; Klein C; Morio T; Picard C Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert Committee. J Hum Immun, 2025.PMID 41608114
- [7]Notarangelo LD Genetically-determined defects of T cell development. Allergy Asthma Proc, 2024.PMID 39294907
- [9]Shearer WT, Fleisher TA, Buckley RH, et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol, 2014.PMID 24582311
- [10]Lankester AC; Neven B; Mahlaoui N; von Asmuth EGJ; Courteille V; Alligon M Hematopoietic cell transplantation in severe combined immunodeficiency: The SCETIDE 2006-2014 European cohort. J Allergy Clin Immunol, 2022.PMID 34718043